Table 4. MGMT activity in peripheral blood mononuclear cells.

	ATase SA (Fm μg−1)			% Activity remaining following
Patient number	Day 0	Day 1	Day 5	Cisplatin	Temozolomide
25#	2.8		7.8		276
2	3.1	3.7	5.5	119	177
24#	3.9	11.9	4.1	309	107
7	3.9	5.4	0.85	140	22
20	3.9		12.1		310
13#	4.3	5.1	0.4	120	9
36	4.9	3.6		74
39	5.9	6.8	1.1	115	19
9	7.1	9.0		127
10#	7.5	3.1	3.1	41	41
38#	7.8	3	1.3	38	17
6#	8.2	9.0	0.7	110	9
15	8.3	14.3	9.0	173	109
4	10.7	10.9	2.6	102	25
17#	11.0	5.4	4.3	49	39
12	12.8	5.5	6.2	43	48
21	12.9
31#	13.1		0.6		5
30#	13.5	35	2.9	259	22
22	15.5	33.3	12	215	77
28	15.9	22.4		141
14	15.9	14.7	5.5	92	35
3	17.5	15.4	10.1	88	57
18	19.2	44.7	4.6	233	24
16#	19.3	13.4	3.3	69	17
23	21.2	18.4		87
29	25.3	33.3		132
11#	27.7	25.2	4.4	91	16
33	28.4	24	31.3	85	110
19	42.2	12.4	14.5	29	34
34	52.5	27.2	12.3	52	24
Mean	14.4	15.4	6.4	116	65
Median	12.8	12.4	4.4	102	34
Range	2.8–52.5	3.0–33.3	<0.4–31.3	29–309%	5–310%

Values in bold are maximum values for sample in # marked patient.